Longevity medicine in 2026

01Key questions

02Combinations Discussed in the Literature

1. Multi-omic blood testing (proteomics, metabolomics, epigenetic clocks, genomics)
2. AI clinical platforms (Longevity AI, Function Health, miora, Tally Health, Protocol.us)
3. Wearable integration (Whoop, Oura, Apple Watch, CGM, continuous monitoring)
4. Physician-oversight + regulatory positioning (concierge, subscription models)

03Pillar 1: Multi-Omic Biological Age Testing

Market Structure (2026)

• 4.2 million biological age tests administered globally as of 2026, with year-on-year growth accelerating.

• Market share by modality (2025): Epigenetic age testing 38.5% | Multi-omics profiling 21.4% | Telomere length analysis 18.2% | Proteomics-based testing 7.3%.
• Fastest-growing segments (CAGR 2026–2034): Proteomics-based testing 16.5% | Multi-omics profiling 14.2% | Epigenetic age testing 9.1%.
• Driver: cost reduction of next-generation sequencing and mass spectrometry platforms making multi-omic panels commercially viable for concierge and DTC channels.

Generations of Epigenetic Clocks

Swipe table →

• Third-generation clocks (2025) achieve all-cause mortality and chronic disease onset predictive AUCs of 0.80–0.87, significantly outperforming chronological age alone.
• Multi-omic biological age composites (epigenomics + proteomics fusion) have achieved AUC >0.91 in validation studies (Nature Aging, 2026).
• Integrated multi-omic composites — particularly DNAm GrimAge combined with metabolomic or proteomic readouts — consistently outperform any single-omic approach, as clock types capture partially non-overlapping biological variance (Broad Institute comparative study).

The EpiAge-R Framework (Yamada, 2026)

Citation: Yamada H. (2026). Epigenetic Clocks, Resilience, and Multi-Omics Ageing: A Review and the EpiAge-R Conceptual Framework. Int J Mol Sci 27(4):1908. DOI: 10.3390/ijms27041908. PMID 41752045. PMCID: PMC12940517.

Core thesis: Current clocks function as odometers (GrimAge) or speedometers (DunedinPACE), capturing accumulated damage or rate of decline — but cannot quantify resilience: the active capacity to recover, reorganize, and maintain homeostasis after stress. Two individuals with identical GrimAge and DunedinPACE scores may have vastly different outcomes after stressors (surgery, infection) due to differing resilience.

Three interacting layers: 1. Molecular — Epigenetic and chromatin resilience (methylation entropy, H3K27ac/H3K9me3 ratio, Lamin A/C integrity, mtDNA copy number, SIRT1/FOXO3 activity) 2. Physiological — Systemic adaptability 3. Environmental — Adaptive context

Key mechanistic insight: Nuclear mechanobiology pathway connects physical damage to inflammation: - ECM degradation → loss of cytoskeletal tension → Lamin A/C downregulation → LAD detachment → heterochromatin decompaction → LINE-1 transposon derepression → cGAS-STING pathway activation ("viral mimicry") → systemic inflammation.

Clinical relevance for longevity clinics: EpiAge-R proposes a Resilience Index distinct from damage scores — potentially the next differentiator for premium clinic offerings once validated. Long-read nanopore sequencing preserves spatial/structural methylation information lost by short-read arrays, enabling higher-resolution biological age assessment.

NAD+ Precursor Differentiation (Berven et al., 2026)

• Berven et al. (iScience, 2026): NR demonstrated superiority over NMN for blood NAD+ elevation (~161% vs 69%) and brain NAD+ trends in healthy/Parkinson's disease cohorts.
• Supports precursor differentiation in clinical protocols; NR may be preferred for blood NAD+ optimization.

04Pillar 2: AI Clinical Platforms

• Molecular You (2026 panel): Emphasizes prioritized interpretation and digital twins for predictive modeling.
• Longevity AI datasets: 1.6M+ records; facilitating biomarker modeling, risk trajectory prediction, and personalized interventions.
• Tally Health, Function Health, miora, Protocol.us: Subscription biological-age tracking with AI-driven intervention recommendations.
• Key 2026 reviews highlight convergence of omics, wearables, and AI in Healthy Longevity Medicine (HLM) as the foundational operating model for next-generation clinics.
• Generative AI / Transformer models are indispensable for optimizing multi-layer weightings and resolving non-linear interactions in multi-omic datasets (Zhavoronkov / PandaOmics and related work).

05Pillar 3: Wearable Integration & Digital Phenotyping

PpgAge — Wearable Aging Clock (Nature Communications, 2025)

Citation: A wearable-based aging clock associates with disease and behavior. Nature Communications (2025). PMCID: PMC12537950.

• Built from photoplethysmography (PPG) data — the optical heart-rate signal captured by every modern smartwatch and ring.
• Trained on 213,593 participants from the Apple Heart & Movement Study, encompassing >149 million participant-days of data.
• Accuracy: Predicted chronological age with mean absolute error (MAE) of 2.42 years (healthy males) and 2.45 years (healthy females); general population MAE 3.13–3.26 years.
• Clinical signal: PpgAge residuals (biological age acceleration) associate with disease prevalence and lifestyle behaviors — validating wearables as a continuous biological-age monitoring modality.

Wearable Clock Ecosystem

Swipe table →

• Wearables enable real-time digital phenotyping (HRV, activity, sleep, gait). Combined with multi-omics, they create longitudinal tracking loops essential for intervention validation.
• All of Us program: digital phenotyping of rest-activity rhythms and biological aging from longitudinal monitoring with commercial wearable devices (medRxiv, 2025).

06Pillar 4: Physician-Oversight & Regulatory Positioning

Clinic Networks (2026)

Swipe table →

Regulatory & Claims Landscape

• FDA SaMD (Software as a Medical Device) oversight for AI clinical decision support — platforms making diagnostic/treatment recommendations may be regulated as medical devices.
• FTC enforcement on unsubstantiated longevity/anti-aging claims (2024–2026 actions). Clinics must anchor claims to validated biomarkers and avoid disease-treatment framing for unapproved interventions.
• Evidence-based interpretation emphasized to mitigate risk; multi-omic panels with AUC >0.91 provide defensible clinical positioning.
• Biological age testing has moved from academic curiosity to actionable clinical/consumer diagnostic category with >4.2M tests administered.

07Build vs Buy / M&A Signals

• AI platforms scaling rapidly; partnerships with concierge practices accelerating.
• Biological age clocks and multi-omic panels driving subscription revenue.
• Proteomics-based testing (16.5% CAGR) and multi-omics (14.2% CAGR) are the highest-growth segments — strategic targets for clinic platform consolidation.
• Long-read sequencing (Oxford Nanopore) may shift epigenetic testing from array-based to sequencing-based, creating platform displacement opportunities.

08Competitive Intelligence Summary

Swipe table →

09Connections

10Sources

1. Yamada H. Int J Mol Sci 27(4):1908, 2026. DOI 10.3390/ijms27041908 . PMID 41752045 .DOI 10.3390/ijms27041908 · PubMed 41752045
2. PMC12940517PMC12940517
3. PpgAge: Nature Communications (2025). PMCID: PMC12537950 .PMC12537950

11Entry history

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.